TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)
Taiwan · Delayed Price · Currency is TWD 8.73
+0.06 (0.69%)
Oct 9, 2025, 1:30 PM CST
TPEX:4157 Revenue
TaiGen Biopharmaceuticals Holdings had revenue of 10.70M TWD in the quarter ending June 30, 2025, a decrease of -91.19%. This brings the company's revenue in the last twelve months to 40.68M, down -72.78% year-over-year. In the year 2024, TaiGen Biopharmaceuticals Holdings had annual revenue of 150.65M with 22.35% growth.
Revenue (ttm)
40.68M
Revenue Growth
-72.78%
P/S Ratio
154.04
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 150.65M | 27.52M | 22.35% |
| Dec 31, 2023 | 123.13M | 86.90M | 239.87% |
| Dec 31, 2022 | 36.23M | -1.26B | -97.20% |
| Dec 31, 2021 | 1.29B | 1.27B | 5,426.95% |
| Dec 31, 2020 | 23.42M | 3.11M | 15.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 44.83M |
| PharmaEssentia | 12.63B |
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| Lumosa Therapeutics | 37.25M |
| Oneness Biotech | 112.57M |
| Polaris Group | 64.02M |
| Center Laboratories | 1.60B |